Skip to main content

Table 1 Data collection from 16 patients with giant cell arteries started on tocilizumab

From: Tocilizumab for relapsing and remitting giant cell arteritis: a case series

 

Patient

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

 

Age

80

80

76

76

79

82

75

72

63

61

72

75

59

76

70

63

 

Sex

M

M

M

F

F

F

F

F

F

F

F

F

M

F

M

F

 

Ethnicity

Other

Arabic

White

Other

White

White

Other

White

Other

White

White

White

White

White

White

White

 

Duration of GCA disease (months) before TOC

5

11

6

25

71

61

1

12

30

7

22

148

52

9

24

24

Medication

Steroid dose at start of TOC (mg)

40

20

40

20

25

10

60

40

5

30

10

30

20

IM 10-weekly

20

20

Most recent steroid dose (mg) and date

0, Aug 2019

5, Feb 2021

7, Feb 2021

0, Feb 2020

10, Jan 2021

2, Nov 2020

3, Jan 2021

10, Feb 2019

5, Dec 2020

10, May 2020

0, May 2020

5, May 2021

10, May 2021

7, March 2021

10, May 2021

Months on TOC

13

18

22

25

12

12

31

12

17

1

17

13

8

15

1

12

Concurrent DMARD dose at TOC start

MTX 15 mg qw

MTX 15 mg qw

 

MTX 25mg qw

Lef 20 mg od

MTX 25 mg qw

Blood results

ESR at presentation

28

49

15

32

55

13

51

60

110

10

63

40

8

38

ESR before start of TOC

2

29

4

32

8.7

5

51

48

10

12

18

16

2

22

13

ESR after start of TOC

2

4

2

20

2

2

42

23

6

2

5

2

2

2

CRP at presentation

403

176

3.5

43

105

10.9

37

128

26

20

49

30

10

63

CRP before start of TOC

7.8

9.1

< 1.0

5.8

3.3

5.1

37

18

< 4.0

8

7.2

4.5

< 4.0

35

20

CRP after start of TOC

< 1.0

0.7

< 1.0

3.3

1.8

1.9

14

3.3

< 4.0

< 1.0

< 4.0

1

< 4.0

1.4

 

Temporal artery biopsy

Neg

Pos

Pos

Neg

Pos

Inconclusive

Inconclusive

Pos

Neg

Neg

Neg-late

Not done

Neg

Not done

Neg

Pos

 

Comorbidities

 

PMR, IHD, PVD

RA

PMR, HypoT

PMR

PMR, HTN

RA

CVA, vasculitis

Takayasu’s arteritis

HypoT

 

PMR

 

PMR

 

PMR

  1. GCA giant cell arteritis, TOC tocilizumab, DMARDs disease modifying antirheumatic drugs, MTX methotrexate, qw once weekly, ESR erythrocyte sedimentation ratio, CRP C-reactive protein, PMR polymyalgia rheumatica, IHD ischemic heart disease, RA rheumatoid arthritis, HTN hypertension, HypoT hypothyroidism, CVA cerebrovascular accident, PVD peripheral vascular disease, Neg negative, Pos positive, Lef leflunomide